Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile

Relmada Therapeutics (RLMD) announced that the pre-planned interim analysis of Reliance II, conducted by the Independent Data Monitoring Committee, indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance.